title: Safety of ultra-rapid intravenous infusion of hepatitis B immunoglobulin in liver transplant recipients.
abstract: OBJECTIVE
  To evaluate the safety of institutional protocol for ultra-rapid hepatitis B immunoglobulin (HBIG) infusion (10,000 IU in 30 minutes) for hepatitis B virus prophylaxis in adult liver transplant recipients.
  
  
  METHODS
  In this case-controlled study, prospectively recruited liver transplant recipients received ultra-rapid infusions of HBIG (10,000 units in 30 minutes) for 6 months. The historical control group consisted of patients who had received 1-hour HBIG infusions (conventional rapid infusion) for the precedent 6 months.
  
  
  RESULTS
  We found that 1472 patients had received 5744 ultra-rapid HBIG infusions, whereas 1343 patients had received 5200 conventional rapid HBIG infusions. Adverse side-effects were observed after 7 (0.13%) and 9 (0.16%) infusions, respectively (P = .763). The number of infusions per month increased significantly, from 878 ± 34 before the introduction of ultra-rapid infusion to 957 ± 29 afterwards (P < .001), an increase of 10.5%. The maximal capacity of HBIG infusions per day in the outpatient clinic increased from 53 for conventional rapid infusion to 65 for ultra-rapid infusion, without expansion of the outpatient facility or equipment.
  
  
  CONCLUSIONS
  Nearly all adult liver recipients able to tolerate 1-hour infusions of HBIG can also tolerate ultra-rapid infusions well. Thus, it seems to be reasonable to perform ultra-rapid infusion protocol widely for patient convenience.
authors.affiliation: Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shwang@amc.seoul.kr
authors.forename: S
authors.initials: S
authors.lastname: Hwang
authors.forename: Y D
authors.initials: YD
authors.lastname: Yu
authors.forename: G C
authors.initials: GC
authors.lastname: Park
authors.forename: Y I
authors.initials: YI
authors.lastname: Choi
authors.forename: P J
authors.initials: PJ
authors.lastname: Park
authors.forename: S W
authors.initials: SW
authors.lastname: Jung
authors.forename: J M
authors.initials: JM
authors.lastname: Namgoong
authors.forename: S Y
authors.initials: SY
authors.lastname: Yoon
authors.forename: H S
authors.initials: HS
authors.lastname: Ha
authors.forename: J J
authors.initials: JJ
authors.lastname: Hong
authors.forename: I O
authors.initials: IO
authors.lastname: Kim
authors.forename: M K
authors.initials: MK
authors.lastname: Jeon
authors.forename: J E
authors.initials: JE
authors.lastname: Ma
authors.forename: S Y
authors.initials: SY
authors.lastname: Choi
authors.forename: J S
authors.initials: JS
authors.lastname: Yun
authors.forename: D H
authors.initials: DH
authors.lastname: Jung
authors.forename: G W
authors.initials: GW
authors.lastname: Song
authors.forename: T Y
authors.initials: TY
authors.lastname: Ha
authors.forename: D B
authors.initials: DB
authors.lastname: Moon
authors.forename: K H
authors.initials: KH
authors.lastname: Kimy
authors.forename: C S
authors.initials: CS
authors.lastname: Ahn
authors.forename: S G
authors.initials: SG
authors.lastname: Lee
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D016031:Liver Transplantation; D011446:Prospective Studies
chemical_list: D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin